Tag: mail

Communiqué de presse – Neuilly-sur-Seine, mercredi 2 juillet 2025 - 17h45

SAN DIEGO, July 02, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, all dates inclusive (the “Class Period”), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI as well as certain of Tempus AI’s top executives with violations of the Securities Exchange Act of 1934.

EDINBURG, Va., July 02, 2025 (GLOBE NEWSWIRE) -- Glo Fiber, powered by Shenandoah Telecommunications Company (“Shentel”) (Nasdaq: SHEN), has launched their 100% fiber optic broadband service in initial neighborhoods in Hillsboro, Ohio. Construction began earlier this year and is expected to be completed in early 2026, providing over 3,000 homes and businesses with a reliable, future-proof option for high-speed internet service. As construction continues, residents will receive advance notice via mail, and they can check availability or sign up for service at www.glofiber.com/en/local/oh/hillsboro.

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) --

Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Sage Therapeutics, Inc. (NASDAQ: SAGE) related to its sale to Supernus Pharmaceuticals, Inc. Upon completion of the proposed transaction, current Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable (i) $0.50 the first commercial sale of the drug Zurzuvae in Japan to third-aprty consumers following regulatory approval on or before June 30, 2026; (ii) $1.00 when net sales of Zurzuvae reach or exceed $300 million in the U.S. on or before December 31, 2028; and (iii) $1.00 when net sales of Zurzuvae reach or exceed $375 million in the U.S. on or before December 31, 2030. Is it a fair deal?